Fanapt Pharmacogenetic Data Suggestive But Not Conclusive, FDA Finds
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA's review of the pharmacogenetic data in Vanda's NDA for Fanapt (iloperidone) suggests that sponsors should be prepared for the agency to require significant clinical evaluation before including pharmacogenetic criteria in labeling
You may also be interested in...
No Comparison: Viibryd’s Path Of Least Resistance Through FDA Could Mean Rocky Marketing
FDA’s statutory neutrality on comparative effectiveness in drug approval decisions both helped and held back Viibryd (vilazodone), now owned by Forest Laboratories. Because approval requires only that a candidate proves superiority to placebo, not to any existing treatments, the antidepressant entered a highly competitive, crowded market with statistically significant but commercially unremarkable efficacy.
No Comparison: Viibryd’s Path Of Least Resistance Through FDA Could Mean Rocky Marketing
FDA’s statutory neutrality on comparative effectiveness in drug approval decisions both helped and held back Viibryd (vilazodone), now owned by Forest Laboratories. Because approval requires only that a candidate proves superiority to placebo, not to any existing treatments, the antidepressant entered a highly competitive, crowded market with statistically significant but commercially unremarkable efficacy.
Pooled Antipsychotic Data Will Be Mined For Early Response Signals
A consortium of international drug companies hopes to leverage their pooled schizophrenia data into a means of determining which patient subgroups are most likely to respond to treatment during clinical trials.